|
1
|
Kamińska E, Janas A and Osica P: Malignant
hyperthermia - problem in dental surgery. An introductory report.
Dev Period Med. 18:483–488. 2014.(In Polish). PubMed/NCBI
|
|
2
|
Riazi S, Kraeva N, Muldoon SM, Dowling J,
Ho C, Petre MA, Parness J, Dirksen RT and Rosenberg H: Malignant
hyperthermia and the clinical significance of type-1 ryanodine
receptor gene (RYR1) variants: proceedings of the 2013 MHAUS
Scientific Conference. Can J Anaesth. 61:1040–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roesl C, Sato K, Schiemann A, Pollock N
and Stowell KM: Functional characterisation of the R2452W ryanodine
receptor variant associated with malignant hyperthermia
susceptibility. Cell Calcium. 56:195–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Han H, Shao J and Zhang M: Diagnosis and
treatment of malignant hyperthermia. Chinese General Medical
Council. 11:314–317. 2008.(In Chinese).
|
|
5
|
Itoh K, Nishibe S, Usuda Y and Kitamura A:
Suspected case of postoperative malignant hyperthermia treated with
dantrolene one week after neurosurgery. Masui. 63:1153–1155.
2014.(In Japanese). PubMed/NCBI
|
|
6
|
Wang Y, Guo X and Luo A: Diagnosis and
treatment progress of malignant hyperthermia. Chinese J
Anesthesiol. 26:92–94. 2006.(In Chinese).
|
|
7
|
Aderibigbe T, Lang BH, Rosenberg H, Chen Q
and Li G: Cost-effectiveness analysis of stocking dantrolene in
ambulatory surgery centers for the treatment of malignant
hyperthermia. Anesthesiology. 120:1333–1338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brislin RP and Theroux MC: Core myopathies
and malignant hyperthermia susceptibility: a review. Paediatr
Anaesth. 23:834–841. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nelson P and Litman RS: Malignant
hyperthermia in children: an analysis of the North American
malignant hyperthermia registry. Anesth Analg. 118:369–374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoppe K, Schleip R, Lehmann-Horn F, Jäger
H and Klingler W: Contractile elements in muscular fascial tissue -
implications for in-vitro contracture testing for malignant
hyperthermia. Anaesthesia. 69:1002–1008. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kazantseva AA and Lebedinskiĭ KM: Modern
diagnostic approaches to malignant hyperthermia susceptibility.
Anesteziol Reanimatol. 59:64–68. 2014.(In Russian). PubMed/NCBI
|
|
12
|
Gillies RL, Bjorksten AR, Du Sart D and
Hockey BM: Analysis of the entire ryanodine receptor type 1 and
alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding
regions for variants associated with malignant hyperthermia in
Australian families. Anaesth Intensive Care. 43:157–166.
2015.PubMed/NCBI
|
|
13
|
Yang Z, Wu X and Huang Z: Retrospective
comparative analysis of malignant hyperthermia. Clin Med
(Northfield, IL). 30:8–11. 2010.
|
|
14
|
Wang YL, Guo XY and Luo AL: Malignant
hyperthermia in Mainland China: an analysis of 34 cases. Chinese
Anesthesiol. 26:107–109. 2006.(In Chinese).
|
|
15
|
Larach MG, Brandom BW, Allen GC, Gronert
GA and Lehman EB: Cardiac arrests and deaths associated with
malignant hyperthermia in North America from 1987 to 2006: a report
from the North American malignant hyperthermia registry of the
malignant hyperthermia association of the United States.
Anesthesiology. 108:603–611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura N, Ueda T, Ishikawa R, Tasaka Y,
Fukuuchi K and Sato N: Malignant hyperthermia developing during
esophageal resection in an 82-year-old man. J Anesth. 22:464–466.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riazi S, Larach MG, Hu C, Wijeysundera D,
Massey C and Kraeva N: Malignant hyperthermia in Canada:
characteristics of index anesthetics in 129 malignant hyperthermia
susceptible probands. Anesth Analg. 118:381–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vigilante JA: Case report: clearance to
dive for a naval candidate with family history of malignant
hyperthermia. Undersea Hyperb Med. 40:365–369. 2013.PubMed/NCBI
|
|
19
|
Sousa CS and Cunha AL: Knowledge of
nursing professionals of a surgical center regarding malignant
hyperthermia. Rev Gaucha Enferm. 35:43–48. 2014.(In Portuguese).
View Article : Google Scholar
|
|
20
|
Rosero EB, Adesanya AO, Timaran CH and
Joshi GP: Trends and outcomes of malignant hyperthermia in the
United States, 2000 to 2005. Anesthesiology. 110:89–94. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bina S, Capacchione J, Munkhuu B, Muldoon
S and Bünger R: Is lymphocyte adenosine a diagnostic marker of
clinical malignant hyperthermia? A pilot study. Crit Care Med.
43:584–593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Larach MG, Brandom BW, Allen GC, Gronert
GA and Lehman EB: Malignant hyperthermia deaths related to
inadequate temperature monitoring, 2007℃2012: a report from the
North American malignant hyperthermia registry of the malignant
hyperthermia association of the United States. Anesth Analg.
119:1359–1366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Z, Fang L and Teng Y: Clinical
diagnosis and treatment of malignant Hyperthermia. J Emerg Med.
16:1226–1227. 2010.
|
|
24
|
Altamirano F, Eltit JM, Robin G, Linares
N, Ding X, Pessah IN, Allen PD and López JR: Ca2+ influx
via the Na+/Ca2+ exchanger is enhanced in
malignant hyperthermia skeletal muscle. J Biol Chem.
289:19180–19190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cain CL, Riess ML, Gettrust L and Novalija
J: Malignant hyperthermia crisis: optimizing patient outcomes
through simulation and interdisciplinary collaboration. AORN J:.
99:301–308. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shaaban S, Ramos-Platt L, Gilles FH, Chan
WM, Andrews C, De Girolami U, Demer J and Engle EC: RYR1 mutations
as a cause of ophthalmoplegia, facial weakness, and malignant
hyperthermia. JAMA Ophthalmol. 131:1532–1540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uchino S, Bellomo R, Morimatsu H, Morgera
S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A,
Oudemans-van SH, Ronco C and Kellum JA: Continuous renal
replacement therapy: A worldwide practice survey. The beginning and
ending supportive therapy for the kidney (B.E.S.T. Kidney)
investigators. Intensive Care Med. 33:1563–1570. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheng R, Jiao JJ and Ting W: Research on
multiple organ dysfunction syndrome with Ulinastatin and continuous
blood purification therapy. J Emerg Med. 17:622–626. 2008.
|
